Feedback Mechanism of Focal Vascular Lesion Formation in Transgenic Apolipoprotein(a) Mice*

Apolipoprotein(a) (apo(a)), the distinguishing protein of atherogenic lipoprotein(a), directs accumulation of the lipoprotein(a) particle to sites in the arterial wall where atherosclerotic lipid lesions develop in man and in transgenic mice expressing human apo(a). It has been proposed that focal apo(a) accumulation in the transgenic mouse vessel wall causes the observed severe local inhibition of transforming growth factor-β (TGF-β) activity and the consequent activation of the smooth muscle cells, which subsequently accumulate lipid to form lesions if the mice are fed a high fat diet. We show that blocking formation of these vascular lesions by two independent mechanisms, tamoxifen treatment and increasing high density lipoprotein, also abolishes apo(a) accumulation, inhibition of TGF-β activity, and activation of smooth muscle cells. The data are consistent with a feedback mechanism in which an initial accumulation of apo(a) inhibits local TGF-β activity, leading to further accumulation of apo(a). Breaking the feedback loop prevents smooth muscle cell activation and therefore lipid lesion development.

[1]  N. Morton,et al.  Lp(a) lipoprotein as a risk factor for myocardial infarction. , 1986, JAMA.

[2]  D. Bellinger,et al.  Occlusive arterial thrombosis in cynomolgus monkeys with varying plasma concentrations of lipoprotein(a). , 1993, Arteriosclerosis and thrombosis : a journal of vascular biology.

[3]  A. Stead,et al.  Lipoprotein(a) serum concentration and apolipoprotein(a) phenotype correlate with severity and presence of ischemic cerebrovascular disease. , 1995, Stroke.

[4]  H. Moses,et al.  Proteolytic activation of latent transforming growth factor-beta from fibroblast-conditioned medium , 1988, The Journal of cell biology.

[5]  D. Rifkin,et al.  Inhibition of endothelial cell movement by pericytes and smooth muscle cells: activation of a latent transforming growth factor-beta 1-like molecule by plasmin during co-culture , 1989, The Journal of cell biology.

[6]  D. Grainger,et al.  A PIVOTAL ROLE FOR TGF‐β* IN ATHEROGENESIS? , 1995 .

[7]  J. Douglas,et al.  Usefulness of serum lipoprotein (a) as a predictor of restenosis after percutaneous transluminal coronary angioplasty. , 1992, The American journal of cardiology.

[8]  R. Lawn,et al.  Activation of transforming growth factor-β is inhibited in transgenic apolipoprotein(a) mice , 1994, Nature.

[9]  P. Libby,et al.  Regulation of smooth muscle cell scavenger receptor expression in vivo by atherogenic diets and in vitro by cytokines. , 1995, The Journal of clinical investigation.

[10]  C. Rosen,et al.  Tamoxifen and estrogen lower circulating lipoprotein(a) concentrations in healthy postmenopausal women. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

[11]  M. Debakey,et al.  Quantitation and localization of apolipoproteins [a] and B in coronary artery bypass vein grafts resected at re-operation. , 1989, Arteriosclerosis.

[12]  J. Gamble,et al.  Endothelial adhesiveness for blood neutrophils is inhibited by transforming growth factor-beta. , 1988, Science.

[13]  G. Owens,et al.  Transforming growth factor-beta-induced growth inhibition and cellular hypertrophy in cultured vascular smooth muscle cells , 1988, The Journal of cell biology.

[14]  G. Proetzel,et al.  Targeted disruption of the mouse transforming growth factor-β1 gene results in multifocal inflammatory disease , 1992, Nature.

[15]  M. Dietel,et al.  Detection and quantification of lipoprotein(a) in the arterial wall of 107 coronary bypass patients. , 1989, Arteriosclerosis.

[16]  M. Sporn,et al.  Hepatic expression of mature transforming growth factor beta 1 in transgenic mice results in multiple tissue lesions. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[17]  S. Hosoda,et al.  Influence of plasma lipoprotein (a) levels on coronary vasomotor response to acetylcholine. , 1995, Journal of the American College of Cardiology.

[18]  S. Schwartz,et al.  Production of transforming growth factor beta 1 during repair of arterial injury. , 1991, The Journal of clinical investigation.

[19]  G. Utermann,et al.  The mysteries of lipoprotein(a). , 1989, Science.

[20]  A. Grace,et al.  The serum concentration of active transforming growth factor-β is severely depressed in advanced atherosclerosis , 1995, Nature Medicine.

[21]  D. Rifkin,et al.  Lipoprotein (a) inhibits the generation of transforming growth factor beta: an endogenous inhibitor of smooth muscle cell migration , 1991, The Journal of cell biology.

[22]  J. Ordovás,et al.  Lipoprotein(a) levels and risk of coronary heart disease in men. The lipid Research Clinics Coronary Primary Prevention Trial. , 1994, JAMA.

[23]  R. Ross The pathogenesis of atherosclerosis: a perspective for the 1990s , 1993, Nature.

[24]  B. Furie,et al.  Antifibrinolytic activity of apolipoprotein(a) in vivo: Human apolipoprotein(a) transgenic mice are resistant to tissue plasminogen activator-mediated thrombolysis , 1995, Nature Medicine.

[25]  P L Weissberg,et al.  Isolation of gene markers of differentiated and proliferating vascular smooth muscle cells. , 1993, Circulation research.

[26]  P. Wilson,et al.  Elevated plasma lipoprotein(a) and coronary heart disease in men aged 55 years and younger. A prospective study. , 1996, JAMA.

[27]  D. Betteridge,et al.  Impairment of endothelium-dependent dilation is an early event in children with familial hypercholesterolemia and is related to the lipoprotein(a) level. , 1994, The Journal of clinical investigation.

[28]  R. Derynck,et al.  Direct transfer of transforming growth factor beta 1 gene into arteries stimulates fibrocellular hyperplasia. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[29]  R. Hammer,et al.  Atherogenesis in transgenic mice expressing human apolipoprotein(a) , 1992, Nature.

[30]  C. Hamm,et al.  Rapid angiographic progression of coronary artery disease in patients with elevated lipoprotein(a) , 1995, Circulation.

[31]  P. Weissberg,et al.  Proliferation of human smooth muscle cells promoted by lipoprotein(a). , 1993, Science.

[32]  D. Grainger,et al.  Tamoxifen elevates transforming growth factor–β and suppresses diet–induced formation of lipid lesions in mouse aorta , 1995, Nature Medicine.

[33]  A. von Eckardstein,et al.  Hypertriglyceridemia and elevated lipoprotein(a) are risk factors for major coronary events in middle-aged men. , 1996, The American journal of cardiology.

[34]  D. Grainger,et al.  Optimization of immunofluorescence methods by quantitative image analysis. , 1996, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[35]  G. McDonald,et al.  The fine structure of human rectal epithelium in acute graft‐versus‐host disease , 1982, The American journal of surgical pathology.

[36]  P. Weissberg,et al.  Tamoxifen decreases the rate of proliferation of rat vascular smooth-muscle cells in culture by inducing production of transforming growth factor beta. , 1993, The Biochemical journal.

[37]  P. Nestel,et al.  Metabolism of Atherogenic Lipoproteins by Smooth Muscle Cells of Different Phenotype in Culture , 1985, Arteriosclerosis.

[38]  A. M. Lefer,et al.  Mechanism of the cardioprotective effect of transforming growth factor beta 1 in feline myocardial ischemia and reperfusion. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[39]  E. Chen,et al.  cDNA sequence of human apolipoprotein(a) is homologous to plasminogen , 1987, Nature.

[40]  B. Nordestgaard,et al.  Specific accumulation of lipoprotein(a) in balloon-injured rabbit aorta in vivo. , 1996, Circulation research.

[41]  R. Assoian,et al.  Transforming growth factor-beta 1 inhibits scavenger receptor activity in THP-1 human macrophages. , 1991, The Journal of biological chemistry.

[42]  S. Schwartz,et al.  Molecular cloning and characterization of 2B7, a rat mRNA which distinguishes smooth muscle cell phenotypes in vitro and is identical to osteopontin (secreted phosphoprotein I, 2aR). , 1991, Biochemical and biophysical research communications.

[43]  R. Nachman Review: Stratton Lecture. Thrombosis and atherogenesis: molecular connections. , 1992, Blood.